沙美特罗替卡松粉吸入剂联合噻托溴铵治疗中重度支气管哮喘疗效及安全性分析

Efficacy and safety analysis of Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation combined with Tiotropium Bromide in the treatment of moderate and severe bronchial asthma

目的探讨沙美特罗替卡松粉吸入剂联合噻托溴铵应用于中重度支气管哮喘治疗中的效果,为临床应用提供参考依据。方法 110例支气管哮喘患者,随机分为研究组和对照组,各55例。对照组在对症支持治疗基础上,予以沙美特罗卡松粉吸入剂雾化吸入;研究组在对照组基础上加用噻托溴铵。比较两组治疗前后肺功能变化及不良反应发生情况。结果治疗前,研究组第1秒用力呼气容积(FEV1)为(1.39±0.19)L、用力肺活量(FVC)为(2.36±0.23)L、峰值呼气流速(PEF)为(2.39±0.35)L/s、最大呼气中段流量(MMEF)为(0.56±0.07)L/s,对照组分别为(1.40±0.18)L、(2.37±0.25)L、(2.40±0.37)L/s、(0.55±0.06)L/s,比较差异均无统计学意义(P>0.05);治疗后,研究组FEV1为(2.89±0.32)L、FVC为(3.99±0.57)L、PEF为(3.89±0.51)L/s、MMEF为(0.97±0.41)L/s,均显著优于对照组的(2.05±0.28)L、(3.12±0.41)L、(3.07±0.47)L/s、(0.83±0.12)L/s,差异均有统计学意义(P<0.05)。且两组均未发现严重不良反应。结论采用沙美特罗卡松粉吸入剂与噻托溴铵联合用药治疗中重度支气管哮喘患者,可显著改善患者肺功能,且用药安全性高,值得临床推广应用。

Objective To investigate the effect of Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation combined with Tiotropium Bromide in the treatment of moderate and severe bronchial asthma,in order to provide reference for clinical application.Methods A total of 110 patients with bronchial asthma were randomly divided into research group and control group,55 cases in each group.The control group received Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation on the basis of symptomatic supportive treatment.The research group was added Tiotropium Bromide on the basis of the control group.The changes of pulmonary function before and after treatment,and the occurrence of adverse reactions between the two groups were compared.Results Before treatment,the forced expiratory volume in 1st second(FEV1),the forced vital capacity(FVC),peak expiratory flow(PEF)and maximum mid-expiratory flow(MMEF)of the research group were(1.39±0.19)L,(2.36±0.23)L,(2.39±0.35)L/s and(0.56±0.07)L/s respectively,those of the control group were(1.40±0.18)L,(2.37±0.25)L,(2.40±0.37)L/s and(0.55±0.06)L/s respectively.There were no statistically significant differences(P>0.05).After treatment,the FEV1,FVC,PEF and MMEF of the research group were(2.89±0.32)L,(3.99±0.57)L,(3.89±0.51)L/s and(0.97±0.41)L/s respectively,which were significantly better than(2.05±0.28)L,(3.12±0.41)L,(3.07±0.47)L/s and(0.83±0.12)L/s of the control group,the differences were statistically significant(P<0.05).No serious adverse reactions were found in the two groups.Conclusion The application of Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation combined with Tiotropium Bromide in the treatment of patients with moderate and severe bronchial asthma can significantly improve the pulmonary function of patients,and has high safety.It is worthy of clinical promotion and application.